Insys Therapeutics competitorsClear all

Insys Therapeutics's top competitors include Assertio Therapeutics, Medivir, Corcept Therapeutics and Bio-Path Holdings.
Insys Therapeutics
Insys Therapeutics
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative supportive care products.
Assertio Therapeutics
Assertio Therapeutics
Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.
Medivir
Medivir
Medivir researches, develops, and sells pharmaceuticals primarily for the treatment of oncology.
Corcept Therapeutics
Corcept Therapeutics
Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.
Bio-Path Holdings
Bio-Path Holdings
Bio-Path Holdings is a clinical and preclinical stage oncology focused antisense drug development company.
Founding Date
Founding Date
1998
Founding Date
1995
Founding Date
1988
Founding Date
1998
Founding Date
2007
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Chandler, US HQ
Round Rock, US
Chandler, US
Locations
Newark, US HQ
Locations
Huddinge, SE HQ
Locations
Menlo Park, US HQ
Locations
Bellaire, US HQ
Employees
Employees
22634% decrease
Employees
11632% decrease
Employees
738% decrease
Employees
16622% increase
Employees
811% decrease
Valuation ($)
Valuation ($)
47.4 m
Valuation ($)
199 m
Valuation ($)
N/A
Valuation ($)
1.2 b
Valuation ($)
66.3 k
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
189
Twitter followers
118
Twitter followers
N/A
Alexa Website Rank
Alexa Website Rank
658340
Alexa Website Rank
552942
Alexa Website Rank
714123
Alexa Website Rank
1121653
Alexa Website Rank
1520286

Financial

Revenue (est.)
Revenue (est.)
$82.1m (FY, 2018)
Revenue (est.)
$311.8m (FY, 2018)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Cost of goods
Cost of goods
$10.8m (FY, 2018)
Cost of goods
$18.5m (FY, 2018)
Cost of goods
N/A
Cost of goods
$5.2m (FY, 2018)
Cost of goods
N/A
Gross profit
Gross profit
$71.3m (FY, 2018)
Gross profit
$293.3m (FY, 2018)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($124.5m) (FY, 2018)
Net income
$36.9m (FY, 2018)
Net income
N/A
Net income
$75.4m (FY, 2018)
Net income
($8.6m) (FY, 2018)

Funding

Total funding raised
Total funding raised
$ 2.3m
Total funding raised
$ 875m
Total funding raised
N/A
Total funding raised
$ 80.1m
Total funding raised
$ 2.3m
For sources of this data, please see the company profile

View company profiles

Assertio Therapeutics
HQ
Newark, US
Employees
116↓ 32% decrease

Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.

View company
Medivir
HQ
Huddinge, SE
Employees
73↓ 8% decrease

Medivir researches, develops, and sells pharmaceuticals primarily for the treatment of oncology.

View company
Corcept Therapeutics
HQ
Menlo Park, US
Employees
166↑ 22% increase

Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.

View company
Bio-Path Holdings
HQ
Bellaire, US
Employees
8↓ 11% decrease

Bio-Path Holdings is a clinical and preclinical stage oncology focused antisense drug development company.

View company